Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana
20 Julho 2023 - 9:05AM
Business Wire
- First blood-only liquid biopsy test for molecular residual
disease now covered for serial testing in patients with stage II or
III colorectal cancer
- Test used after surgery or curative treatment to inform
physician decisions about adjuvant therapy and to monitor for
disease progression, recurrence or relapse
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, announced today that Blue Cross and Blue Shield of
Louisiana now offers coverage for the Guardant Reveal™ molecular
residual disease (MRD) test. Guardant Reveal is a blood test that
detects circulating tumor DNA (ctDNA) in blood after treatment,
including surgery, to help oncologists identify cancer patients
with residual or recurring disease who may benefit most from
adjuvant therapy or surveillance. It was the first blood-only
liquid biopsy test commercially available for MRD testing.
Effective July 10, Blue Cross and Blue Shield of Louisiana is
providing coverage for the Guardant Reveal test for individuals
with stage II or III colorectal cancer after curative treatment
(including surgery) to inform physician decisions about
post-treatment therapy and to monitor for disease progression,
recurrence or relapse. The frequency of testing covered is aligned
with monitoring guidelines established by the National
Comprehensive Cancer Network (NCCN) for colorectal cancer. It
includes the initial ctDNA test 4 to 6 weeks after surgery (or 2 to
4 weeks after completion of systemic therapy) and thereafter every
3 to 6 months for the first two years, and every 6 to 12 months for
the following 3 years.
“We are pleased that Blue Cross and Blue Shield of Louisiana has
taken this important step to make blood testing for residual
disease more accessible,” said Helmy Eltoukhy, Guardant Health
chairman and co-CEO. “This will help oncologists make more informed
decisions about treatment and monitoring for colorectal cancer
patients and survivors.”
Blue Cross and Blue Shield of Louisiana serves approximately 1.9
million members. This policy decision adds to the payor coverage of
Guardant Reveal, which received Medicare coverage in August
2022.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
tests, vast data sets and advanced analytics. The Guardant Health
oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched Guardant360®, Guardant360 CDx,
Guardant360 TissueNext™, Guardant360 Response™, and
GuardantINFINITY® tests for advanced stage cancer, and Guardant
Reveal™ for early-stage cancer. The Guardant Health screening
portfolio, including the commercially launched Shield™ test, aims
to address the needs of individuals eligible for cancer screening.
For more information, visit guardanthealth.com and follow the
company on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2022, and any
current and periodic reports filed with or furnished to the
Securities and Exchange Commission thereafter. The forward-looking
statements in this press release are based on information available
to Guardant Health as of the date hereof, and Guardant Health
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing Guardant Health’s views
as of any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230720806084/en/
Investor Contact: Alex Kleban
investors@guardanthealth.com +1 657-254-5417
Media Contact: Michael Weist press@guardanthealth.com +1
650-647-3643
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024